Home > Boards > US OTC > Electronics and components >

Patriot Scientific (PTSC)

PTSC RSS Feed
Add PTSC Price Alert      Hide Sticky   Hide Intro
Moderator: MightySam
Search This Board: 
Last Post: 9/20/2020 9:07:42 AM - Followers: 258 - Board type: Free - Posts Today: 0

About the incoming Merging Entity - Mosaic ImmunoEngineering Inc. https://www.mosaicie.com/about


Current Programs


MOSAIC LEADERSHIPhttps://www.mosaicie.com/leadership


KEY PUBLICATIONS AND GRANTS - https://www.mosaicie.com/publications




MOSAIC ENGINEERING RECENT NEWS
 

Mosaic ImmunoEngineering Inc. signs license-option to advance novel immunotherapy to treat cancer and infectious diseases


https://thedaily.case.edu/mosaic-immunoengineering-inc-signs-license-option-to-advance-novel-immunotherapy-to-treat-cancer-and-infectious-diseases/

Agreement with CWRU Technology Transfer Office and Dartmouth College
Mosaic ImmunoEngineering Inc., a private biotechnology company based in Novato, California, has signed a two-year option agreement with Case Western Reserve University and Dartmouth College, granting the company the exclusive right to license technology for a novel platform technology using virus-like nanoparticles (“VLP”) to treat and prevent cancer and infectious diseases in humans and for veterinary use.

The technology has broad potential to treat many different types of cancer and is supported by numerous scientific publications and grant funding. The technology also has direct application as part of a vaccine platform, which has generated promising data in both cancer and infectious diseases, including COVID-19, through research funded by the National Science Foundation (NSF).

An option agreement provides Mosaic two years to obtain a full license agreement. A license option typically is granted to a company interested in further evaluation of the technology before entering into a full license agreement that allows the company to commercially market it. The two-year option to license agreement, is managed through Case Western Reserve’s Technology Transfer Office.

“Along with providing world-class research in many areas, Case Western Reserve University and Dartmouth College are striving to translate these exciting discoveries into products that can make a difference in the lives of patients with life threatening illnesses,” said Wayne Hawthorne, senior licensing manager in the university’s Technology Transfer Office. “We encourage our faculty to conduct basic research which can become the basis of discoveries that have direct application to clinical needs such as the technology that Mosaic is seeking to advance. Considerable research and progress was made on the technology through internal awards and grants that funded early product development and clinical proof from organizations such Coulter Foundation, Council to Advance Human Health and Ohio Third Frontier Technology Validation and Start-Up Fund.”

The inventors of the technology include Nicole Steinmetz, professor in the Department of NanoEngineering and director of the Center for Nano-ImmunoEngineering at the University of California San Diego (UCSD), and Jonathan Pokorski, associate professor in the Department of NanoEngineering at UCSD. During their tenure at Case Western Reserve, they worked in conjunction with Steven Fiering, a professor of microbiology and immunology at Dartmouth Geisel School of Medicine.

The researchers have collectively demonstrated that plant-derived, engineered VLP-based nanotechnologies stimulate a potent anti-tumor immune response in mouse models of metastatic melanoma, ovarian cancer, colon cancer, brain cancer and breast cancer, including companion dogs with metastatic melanoma. This data supports the potential to translate preclinical studies into veterinary applications, such as the treatment of cancer in companion animals, which has high relevance to human melanoma.

“We are pleased to have completed this agreement with CWRU and Dartmouth, and look forward to working closely with the university and Drs. Steinmetz, Pokorski and Fiering to rapidly advance the highly promising technology platforms into the clinic,” said Steven King, co-founder and chief executive officer of Mosaic. “This technology platform includes many opportunities in oncology and infectious diseases, including both human and veterinary applications. This is a very important milestone for Mosaic, and we are very happy to have the opportunity to work with prestigious universities and an impressive team of scientists.”

“This immuno-oncology approach provides a personalized treatment approach by relieving the patient’s tumor-mediated immunosuppression and potentiating anti-tumor immunity against antigens expressed by their own tumor,” said Steinmetz, a co-inventor of the technology and a co-founder and chief scientific officer of Mosaic. “The vaccine platform is a natural extension of the immune-stimulating properties of the VLP, combined with directing the response to pre-defined targets. Instead of being a personal vaccine, the modular approach of linking disease specific targets to the VLP allows the potential to rapidly develop countermeasures for pandemics such as COVID-19.”

Mosaic, through its founding team, has identified a lead oncology candidate for advancement into clinical trials and the ongoing NSF funded research is supporting the application of the technology toward the development of a SARS-CoV-2 vaccine for the prevention of COVID-19. Over the past 10 years, the technology has been funded through numerous research grants totaling more than $20 million.

For more information, contact Bill Lubinger at william.lubinger@case.edu.
PTSC
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#22940  Sticky Note Nice news out!!! MightySam 08/31/20 12:14:42 PM
#22958   You can take your manure and load it Ubgood 09/20/20 09:07:42 AM
#22957   Far from bottom here on this piece of Ubgood 09/18/20 11:22:00 AM
#22956   eh. Mistakes happen. potofgold 09/18/20 09:58:48 AM
#22955   I'll retract that statement. It is September 30th MightySam 09/18/20 09:51:37 AM
#22954   I didn't know that. Not that I looked potofgold 09/18/20 09:36:51 AM
#22953   Yeah i hope so too. The 8-k had MightySam 09/18/20 09:25:05 AM
#22952   Hopefully. PTSC did have a quarter that ended potofgold 09/17/20 05:55:08 PM
#22951   Bottoms looks to be in here. We should MightySam 09/17/20 01:44:19 PM
#22950   Search list of crooks!! It should come Up.. Ubgood 09/14/20 07:56:31 AM
#22949   It's weird. You can't bring up the PTSC potofgold 09/11/20 01:35:16 PM
#22948   This road was traveled before with a pharma Ubgood 09/07/20 08:26:41 PM
#22947   PTSCs asset? Gullible.DEEPLY.underwater.shareholders.willing to.believe ANYTHING! and double down. Neverending 09/07/20 07:55:26 PM
#22946   Its trash run by crooks!! That's the bottom line.. Ubgood 09/07/20 09:33:14 AM
#22945   Obviously you haven't done your DD. $PTSC will MightySam 09/04/20 01:04:43 PM
#22944   Looks like another pharma scam about to be Ubgood 09/04/20 06:49:49 AM
#22943   Must read on Incoming merger company and it's MightySam 09/01/20 01:57:44 PM
#22942   So, if I understand this right, Moasic hooks potofgold 09/01/20 11:20:17 AM
#22941   $PTSC Filings hit!! MightySam 08/31/20 03:42:24 PM
#22940   Nice news out!!! MightySam 08/31/20 12:14:42 PM
#22939   Have you looked in a mirror lately..talk about Ubgood 08/31/20 06:44:47 AM
#22938   Must be paid pumping clown!! Seems this Ubgood 08/29/20 07:21:48 AM
#22937   $PTSC .01 coming fast Smokin1000 08/28/20 12:36:25 PM
#22936   Penny break here!!! MightySam 08/28/20 10:03:27 AM
#22935   Penny break here!!! MightySam 08/28/20 10:03:27 AM
#22934   When is the hearing? BullsMD 08/28/20 08:51:15 AM
#22933   Another musical chairs shift!! Seen this before..scammers!! Ubgood 08/27/20 04:24:59 PM
#22932   Another musical chairs shift!! Seen this before..scammers!! Ubgood 08/27/20 04:11:19 PM
#22931   Remember Carlton Johnson vacates his duties as an MightySam 08/27/20 03:20:01 PM
#22930   Buy you some. New management taking over here. MightySam 08/27/20 03:16:20 PM
#22929   $PTSC quiet loading. These prices will be unheard MightySam 08/27/20 03:15:48 PM
#22928   Johnson has been on board of other companies Ubgood 08/27/20 11:29:50 AM
#22927   Nice run! BUT u.would be a FOOL.to hold it! Neverending 08/26/20 08:03:58 PM
#22926   Stupid is the one not making money. Dope Thehustle 08/26/20 03:07:39 PM
#22925   Looks like you get more shares...Lol. footballref-8541 08/26/20 12:32:41 PM
#22924   I'll jump back before the hearing on the EC Mark102 08/26/20 12:30:51 PM
#22923   This merger is definitely a positive for PTSC Prudent Capitalist 08/26/20 12:09:42 PM
#22922   What’s going Mark, give up on Jcp? footballref-8541 08/26/20 11:51:20 AM
#22921   Mosaic's current President and CEO Steven King was MightySam 08/26/20 11:26:35 AM
#22920   Mosaic Engineering Technology from site MightySam 08/26/20 10:37:59 AM
#22919   Stupidly undervalued here. Look at their publications and MightySam 08/26/20 10:34:52 AM
#22918   Going to need 4 billion commons at this roytoy6969 08/26/20 09:12:42 AM
#22917   Nicole F. Steinmetz, Ph.D. MightySam 08/26/20 09:01:35 AM
#22916   Guys some heavy hitters in Mosaic's leadership. Check MightySam 08/26/20 09:00:31 AM
#22915   Gm abazaba375 08/26/20 08:30:34 AM
#22914   You just can't fix stupid..I have to stop trying.. Ubgood 08/26/20 07:52:15 AM
#22913   Na, but can you recommend where I should Thehustle 08/26/20 06:53:35 AM
#22912   I have recommended therapy to a lot other Ubgood 08/25/20 07:21:48 PM
#22911   Read it 5 times. Buying at open. Mark102 08/25/20 06:53:06 PM
#22910   Read the 8-K .. this is all good Timing101 08/25/20 06:38:02 PM
#22909   You totally space PTSC off for a couple potofgold 08/25/20 06:32:17 PM
PostSubject
Consent Preferences